首页> 外文期刊>Tumour biology : >Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach
【24h】

Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach

机译:基于质谱的比较蛋白质组学方法鉴定RAB2A和PRDX1作为口腔鳞状细胞癌的潜在生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Despite the recent advances in diagnostic and therapeutic strategies, oral squamous cell carcinoma (OSCC) remains a major health burden. Protein biomarker discovery for early detection will help to improve patient survival rate in OSCC. Mass spectrometry-based proteomics has emerged as an excellent approach for detection of protein biomarkers in various types of cancers. In the current study, we have used 4-Plex isobaric tags for relative and absolute quantitation (iTRAQ)-based shotgun quantitative proteomic approach to identify proteins that are differentially expressed in cancerous tissues compared to normal tissues. The high-resolution mass spectrometric analysis resulted in identifying 2,074 proteins, among which 288 proteins were differentially expressed. Further, it was noticed that 162 proteins were upregulated, while 125 proteins were downregulated in OSCC-derived cancer tissue samples as compared to the adjacent normal tissues. We identified some of the known molecules which were reported earlier in OSCC such as MMP-9 (8.4-fold), ZNF142 (5.6-fold), and S100A7 (3.5-fold). Apart from this, we have also identified some novel signature proteins which have not been reported earlier in OSCC including ras-related protein Rab-2A isoform, RAB2A (4.6-fold), and peroxiredoxin-1, PRDX1 (2.2-fold). The immunohistochemistry-based validation using tissue microarray slides in OSCC revealed overexpression of the RAB2A and PRDX1 gene in 80 and 68 % of the tested clinical cases, respectively. This study will not only serve as a resource of candidate biomarkers but will contribute towards the existing knowledge on the role of the candidate molecules towards disease progression and therapeutic potential.
机译:尽管最近在诊断和治疗策略上取得了进步,但是口腔鳞状细胞癌(OSCC)仍然是主要的健康负担。早期发现蛋白质生物标志物将有助于提高OSCC患者的生存率。基于质谱的蛋白质组学已成为检测各种类型癌症中蛋白质生物标志物的一种极佳方法。在当前的研究中,我们已使用4-Plex等压标记进行基于相对和绝对定量(iTRAQ)的shot弹枪定量蛋白质组学方法,以鉴定与正常组织相比在癌组织中差异表达的蛋白质。高分辨率质谱分析鉴定出2,074个蛋白质,其中288个蛋白质差异表达。此外,注意到与邻近的正常组织相比,在OSCC来源的癌组织样品中162种蛋白被上调,而125种蛋白被下调。我们确定了OSCC中较早报道的一些已知分子,例如MMP-9(8.4倍),ZNF142(5.6倍)和S100A7(3.5倍)。除此之外,我们还鉴定了OSCC中较早未报道的一些新型特征蛋白,包括ras相关蛋白Rab-2A亚型,RAB2A(4.6倍)和过氧化物酶1(PRDX1)(2.2倍)。在OSCC中使用组织微阵列玻片进行的基于免疫组织化学的验证表明,分别在80%和68%的受试临床病例中RAB2A和PRDX1基因过表达。这项研究不仅将用作候选生物标志物的资源,而且将有助于增加有关候选分子对疾病进展和治疗潜力的作用的现有知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号